This is the authors' abstract. We don't add key points for this paper.
patient cohort with 35 KTRs with biopsy proven TCMRs, 3 KTRs diagnosed with borderline TCMR, 1 mixed AMR/TCMR rsp. AMR/borderline TCMR and 13 control patients with a rejection-free kidney graft proven by protocol biopsies. The new point-of-care assay showed a specificity of 84.6% and sensitivity of 87.5%, and a superior estimated glomerular filtration rate (eGFR) at the time point of biopsy (specificity 30.8%, sensitivity 85%).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Seiler et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: